Canadian clinical-stage biotechnology company Clearmind Medicine Inc. (NASDAQ: CMND, FSE: CWY0) announced on Tuesday that it has begun patient enrolment at Tel Aviv Sourasky Medical Center for its FDA-approved Phase I/IIa trial of CMND-100 in Alcohol Use Disorder.
The activation of the Israeli site, led by Principal Investigator Prof. David Zeltser, adds to a network that includes Yale School of Medicine, Johns Hopkins University School of Medicine, and Hadassah Medical Center.
The study is assessing the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, a proprietary non-hallucinogenic oral MEAI-based compound.
Clearmind reported that top-line findings from the first completed cohort showed favourable safety and adherence with no serious adverse events.
The company, which develops psychedelic-derived therapeutics for under-treated conditions, holds a portfolio of nineteen patent families and 31 granted patents as it advances its therapeutic pipeline.
Active Biotech to receive US patent for tasquinimod formulation
Sanofi and Regeneron's Dupixent approved in EU for chronic spontaneous urticaria
Clearmind Medicine advances global CMND-100 AUD trial with first patient enrolled in Israel
NeuroSense's PrimeC receives FDA clearance for pivotal Phase 3 trial in ALS
Made Scientific enters manufacturing partnership with Cellergy Therapeutics
Novartis' Itvisma granted US FDA approval for spinal muscular atrophy treatment
Avidity Biosciences announces US Managed Access Program for delpacibart zotadirsen (del-zota)
Mycovia Pharmaceuticals publishes long-term efficacy results from extension study of VIVJOA
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
AbbVie receives approval for EPKINLY, rituximab and lenalidomide combination
European Commission approves Celltrion's Remsima IV liquid formulation